The global onychomycosis treatment market is estimated to be valued at USD 3,755 Mn in 2026 and is projected to grow at a compound annual growth rate (CAGR) of 5.6% during the forecast period (2026-2033), surpassing USD 5,497 Mn by 2033.
Onychomycosis Treatment Market is influenced by the rise in the incidence of fungal nail infections, the rise in geriatric population, rising incidence of diabetes, and increased awareness about early detection and treatment. Innovation in topical antifungal drugs, advanced drug delivery systems, and availability of both prescribed as well as over-the-counter treatments are contributing to the growth of this market. The long duration of treatment, re-infection, and ineffectiveness of certain treatments pose challenges for the market. There are new opportunities available in the form of novel topical formulations and laser treatment modalities.
According to the Treatment Type, Drugs will lead the market and are projected to have a share of more than 80.0% of the total market revenues in 2026. This segment's leading position is attributed to the high efficacy of oral anti-fungal drugs such as terbinafine and itraconazole. In addition, increasing use of innovative topical treatments that allow for better nail penetration is boosting market revenues.
According to the Type, Distal Subungual Onychomycosis will hold a share of about 74.0% of the market in 2026. The segment will dominate due to its position as the most common type of nail fungus infection, especially of the toenail. Increasing prevalence among older people, diabetics, and immunocompromised patients drives the need for treatment solutions.
On a regional basis, North America is anticipated to hold a dominant position in the onychomycosis treatments market by occupying a 40.0% market share in 2026 due to high uptake of novel topical antifungal drug treatments, high prescription of oral drugs, good reimbursement scenario, and growing aged and diabetic population. On the other hand, Asia Pacific is anticipated to witness highest growth in terms of percentage and holds 22.0% of the market in 2026 owing to huge patient pool, high prevalence of OTC antifungal drugs, growing self-medication, high healthcare awareness, and fast growth of e-pharmacy services.
Prominent Players in the Onychomycosis Treatment Market
-
Lumenis Ltd.
Company Overview
- Headquarters: Yokneam Illit, Israel
- Establishment Year: 1966
- Employee Strength: Approximately 1,500 employees
- Leadership: Mr. Tzipi Ozer-Armon, Chief Executive Officer
- Core Services/Products: Energy-based medical devices, laser systems, intense pulsed light (IPL) technologies, dermatology solutions, aesthetic devices, and laser treatments for onychomycosis.
SWOT Analysis
- Strengths
- Largest provider of lasers and other medical devices using technology that includes dermatology.
- Highly effective minimally invasive treatment for fungal nail infection.
- Weaknesses
- Heavy reliance on sales of capital equipment to healthcare facilities.
- Expensive prices affect the affordability of its devices.
- Opportunities
- Sales growth of lasers to treat onychomycosis.
- Increased operations in emerging aesthetic and dermatology markets.
- Threats
- Pharmaceutical antifungal medications as well as laser companies.
- Stringent medical device regulations.
-
Cipla Ltd.
Company Overview
- Headquarters: Mumbai, Maharashtra, India
- Establishment Year: 1935
- Employee Strength: Approximately 28,000 employees
- Leadership: Mr. Umang Vohra, Managing Director & Global Chief Executive Officer
- Core Services/Products: Generic pharmaceuticals, prescription medicines, dermatology products, antifungal therapies, respiratory medicines, and active pharmaceutical ingredients (APIs).
